News
AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AstraZeneca PLC (NASDAQ:AZN ...
AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...
AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...
1d
Zacks Investment Research on MSNAstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage StudiesAstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...
Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...
AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...
AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...
Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...
AstraZeneca PLC closed 20.36% short of its 52-week high of £133.88, which the company achieved on September 3rd.
AstraZeneca’s contract to supply the UK with 100 million Covid-19 vaccine doses commits it to making “best reasonable efforts,” the same language used in its deal with the European Union ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results